167 related articles for article (PubMed ID: 31872559)
21. NFAT2 inhibitor ameliorates diabetic nephropathy and podocyte injury in db/db mice.
Zhang L; Li R; Shi W; Liang X; Liu S; Ye Z; Yu C; Chen Y; Zhang B; Wang W; Lai Y; Ma J; Li Z; Tan X
Br J Pharmacol; 2013 Sep; 170(2):426-39. PubMed ID: 23826864
[TBL] [Abstract][Full Text] [Related]
22. Probucol in Albuminuric Type 2 Diabetes Mellitus Patients on Renin-Angiotensin System Blockade: A 16-Week, Randomized, Double-Blind, Placebo-Controlled Trial.
Jin SM; Han KA; Yu JM; Sohn TS; Choi SH; Chung CH; Park IeB; Rhee EJ; Baik SH; Park TS; Lee IK; Ko SH; Hwang YC; Cha BS; Lee HW; Nam MS; Lee MK
Arterioscler Thromb Vasc Biol; 2016 Oct; 36(10):2108-14. PubMed ID: 27493100
[TBL] [Abstract][Full Text] [Related]
23. Effect of pitavastatin on urinary liver-type fatty acid-binding protein levels in patients with early diabetic nephropathy.
Nakamura T; Sugaya T; Kawagoe Y; Ueda Y; Osada S; Koide H
Diabetes Care; 2005 Nov; 28(11):2728-32. PubMed ID: 16249547
[TBL] [Abstract][Full Text] [Related]
24. Lysophosphatidic acid receptor 1 inhibitor, AM095, attenuates diabetic nephropathy in mice by downregulation of TLR4/NF-κB signaling and NADPH oxidase.
Lee JH; Sarker MK; Choi H; Shin D; Kim D; Jun HS
Biochim Biophys Acta Mol Basis Dis; 2019 Jun; 1865(6):1332-1340. PubMed ID: 30763641
[TBL] [Abstract][Full Text] [Related]
25. Critical role for osteopontin in diabetic nephropathy.
Nicholas SB; Liu J; Kim J; Ren Y; Collins AR; Nguyen L; Hsueh WA
Kidney Int; 2010 Apr; 77(7):588-600. PubMed ID: 20130530
[TBL] [Abstract][Full Text] [Related]
26. Involvement of heparan sulfate in the renoprotective effects of imidapril, an angiotensin-converting enzyme inhibitor, in diabetic db/db mice.
Yoneda H; Ueta K; Nagasaki M; Arakawa K
J Recept Signal Transduct Res; 2014 Feb; 34(1):21-5. PubMed ID: 24094140
[TBL] [Abstract][Full Text] [Related]
27. Enhanced vascular chymase-dependent conversion of endothelin in the diabetic kidney.
Harrison-Bernard LM; de Garavilla L; Bivona BJ
Ochsner J; 2013; 13(1):49-55. PubMed ID: 23532714
[TBL] [Abstract][Full Text] [Related]
28. Chymase inhibition reduces the progression to heart failure after autoimmune myocarditis in rats.
Palaniyandi SS; Nagai Y; Watanabe K; Ma M; Veeraveedu PT; Prakash P; Kamal FA; Abe Y; Yamaguchi K; Tachikawa H; Kodama M; Aizawa Y
Exp Biol Med (Maywood); 2007 Oct; 232(9):1213-21. PubMed ID: 17895529
[TBL] [Abstract][Full Text] [Related]
29. ACE-dependent and chymase-dependent angiotensin II generation in normal and glucose-stimulated human mesangial cells.
Cristovam PC; Arnoni CP; de Andrade MC; Casarini DE; Pereira LG; Schor N; Boim MA
Exp Biol Med (Maywood); 2008 Aug; 233(8):1035-43. PubMed ID: 18480420
[TBL] [Abstract][Full Text] [Related]
30. Sulodexide ameliorates early but not late kidney disease in models of radiation nephropathy and diabetic nephropathy.
Rossini M; Naito T; Yang H; Freeman M; Donnert E; Ma LJ; Dunn SR; Sharma K; Fogo AB
Nephrol Dial Transplant; 2010 Jun; 25(6):1803-10. PubMed ID: 20061322
[TBL] [Abstract][Full Text] [Related]
31. Enalapril improves albuminuria by preventing glomerular loss of heparan sulfate in diabetic rats.
Reddi AS; Ramamurthi R; Miller M; Dhuper S; Lasker N
Biochem Med Metab Biol; 1991 Feb; 45(1):119-31. PubMed ID: 2015105
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of C-jun N-terminal kinase improves insulin sensitivity but worsens albuminuria in experimental diabetes.
Ijaz A; Tejada T; Catanuto P; Xia X; Elliot SJ; Lenz O; Jauregui A; Saenz MO; Molano RD; Pileggi A; Ricordi C; Fornoni A
Kidney Int; 2009 Feb; 75(4):381-8. PubMed ID: 18971923
[TBL] [Abstract][Full Text] [Related]
33. Chymase as a Possible Therapeutic Target for Amelioration of Non-Alcoholic Steatohepatitis.
Takai S; Jin D
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33066113
[TBL] [Abstract][Full Text] [Related]
34. Low nitric oxide bioavailability upregulates renal heparin binding EGF-like growth factor expression.
Miyazawa T; Zeng F; Wang S; Fan X; Cheng H; Yang H; Bian A; Fogo AB; Harris RC
Kidney Int; 2013 Dec; 84(6):1176-88. PubMed ID: 23760291
[TBL] [Abstract][Full Text] [Related]
35. SGLT2 Inhibitor Empagliflozin and DPP4 Inhibitor Linagliptin Reactivate Glomerular Autophagy in
Korbut AI; Taskaeva IS; Bgatova NP; Muraleva NA; Orlov NB; Dashkin MV; Khotskina AS; Zavyalov EL; Konenkov VI; Klein T; Klimontov VV
Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32340263
[TBL] [Abstract][Full Text] [Related]
36. Olmesartan Prevents Microalbuminuria in db/db Diabetic Mice Through Inhibition of Angiotensin II/p38/SIRT1-Induced Podocyte Apoptosis.
Gu J; Yang M; Qi N; Mei S; Chen J; Song S; Jing Y; Chen M; He L; Sun L; Hu H; Li L; Wüthrich RP; Wu M; Mei C
Kidney Blood Press Res; 2016; 41(6):848-864. PubMed ID: 27871084
[TBL] [Abstract][Full Text] [Related]
37. Amelioration of long-term renal changes in obese type 2 diabetic mice by a neutralizing vascular endothelial growth factor antibody.
Flyvbjerg A; Dagnaes-Hansen F; De Vriese AS; Schrijvers BF; Tilton RG; Rasch R
Diabetes; 2002 Oct; 51(10):3090-4. PubMed ID: 12351452
[TBL] [Abstract][Full Text] [Related]
38. NF-κB Inhibitor Parthenolide Promotes Renal Tubules Albumin Uptake in Type 2 Diabetic Nephropathy.
Hao QF; Wang BB; Zhang W; Qiu W; Liu QL; Li XM
Chin Med Sci J; 2020 Mar; 35(1):31-42. PubMed ID: 32299536
[TBL] [Abstract][Full Text] [Related]
39. Depressor effect of chymase inhibitor in mice with high salt-induced moderate hypertension.
Devarajan S; Yahiro E; Uehara Y; Habe S; Nishiyama A; Miura S; Saku K; Urata H
Am J Physiol Heart Circ Physiol; 2015 Dec; 309(11):H1987-96. PubMed ID: 26432844
[TBL] [Abstract][Full Text] [Related]
40. Effects of chymostatin, a chymase inhibitor, on blood pressure, plasma and tissue angiotensin II, renal haemodynamics and renal excretion in two models of hypertension in the rat.
Roszkowska-Chojecka MM; Walkowska A; Gawryś O; Baranowska I; Kalisz M; Litwiniuk A; Martyńska L; Kompanowska-Jezierska E
Exp Physiol; 2015 Sep; 100(9):1093-105. PubMed ID: 26011164
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
